

PRESS RELEASE

(SRP/PR/0902/001)

5 March 2009

SINGAPORE RADIOPHARMACEUTICALS PTE LTD INAUGURATION AT SINGAPORE SCIENCE PARK II

Singapore Radiopharmaceuticals Pte Ltd has established a S\$10.8 million (US\$7.1 million) state-of-the-art cyclotron and central radiopharmacy facility at Singapore Science Park II for the production of advance positron-emission tomography (PET) radiopharmaceuticals for molecular imaging of cancer, heart and brain diseases and biomedical research.

Professor Sir George Radda (CBE, FRS), Chairman, Singapore Bioimaging Consortium, officially inaugurated the opening of SRP at Singapore Science Park II on 5 March 2009. The latter is strategically located in Singapore's world class medical and biomedical research cluster centered on the National University Health System, the National University of Singapore, the Biopolis biomedical research hub and the Nanyang Technological University.

"The value of our investment and the scale of its capabilities signal our commitment to produce advance radiopharmaceuticals, not presently available in the region, for cutting edge molecular imaging, diagnosis, monitoring and research of cancer, heart and brain diseases," said Chan Wai Chuen, Managing Director of Singapore Radiopharmaceuticals. "SRP will enhance Singapore's strong international reputation by expanding the range of medical diagnostic and treatment options."

"We welcome Singapore Radiopharmaceutical's facility which supports our mission to foster closer collaboration in bioimaging amongst researchers and medical practitioners," said Professor Sir George Radda (CBE, FRS), Chairman, Singapore Bioimaging Consortium. "The facility's capabilities will support the growth of multi-disciplinary research activities and speed the development and translation of biomedical research discoveries into clinical applications."

SRP's 434 square meter facility consists of a 16.5 MeV General Electric PETtrace cyclotron and a central radiopharmacy. It has two synthesis clean rooms with automatic synthesis modules for the production of 18F-FDG (fluorine-18 fluorodeoxyglucose) and other advance PET radiopharmaceuticals. Stringent quality control is accomplished by advance analytical instruments such as radio-HPLC (high performance liquid chromatography), gas chromatography, GC-MS (mass spectrometry) and gamma spectroscopy. These are supported by a chemistry laboratory, clean rooms for sterile preparation and assembly of raw materials.

SRP has a team of highly qualified radiochemists, medical physicist, cyclotron operation and quality control specialists and laboratory technicians to attend to the operational and safety needs of the cyclotron and quality control of radiopharmaceutical production.

International experts are preparing cGMP (good manufacturing practice) policies, practices and documents for cGMP-compliant production of sterile radiopharmaceuticals.

Production of PET-radiopharmaceuticals begins in March 2009.

Singapore Radiopharmaceuticals Pte Ltd

Singapore Radiopharmaceuticals Pte Ltd is located at #01-15/16, The Gemini, 41 Science Park Road, Science Park II, Singapore 117610.

It produces advance radiopharmaceuticals for PET (positron-emission tomography), SPECT (single-photon emission tomography) and IRT (internal radiation therapy) for Oncology, Cardiology, Neurology and various other diseases. It also aims to establish collaborations with local and oversea hospitals, pharmaceutical companies, research institutes and academic institutes for the advancement of molecular imaging, nuclear medicine and radiopharmaceutical chemistry.

For more information visit us at www.radiopharmaceuticals.com.sg,

or contact

1. Dr Maung Maung Saw
Director
Singapore Radiopharmaceuticals Pte Ltd
email: mmsaw@radiopharmaceuticals.com.sg
2. Mr Hyder Mukhthar
Group Markets and Business Development Manager
RadLink Diagnostic Imaging (S) Pte Ltd
mobile: 9833 3384
email: hyder@radlink.com.sg

-END OF DOCUMENT-